Increased MIB-1 expression in salivary gland pleomorphic adenoma that recurs and undergoes malignant transformation.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 05 2022
30 05 2022
Historique:
received:
13
02
2022
accepted:
13
05
2022
entrez:
31
5
2022
pubmed:
1
6
2022
medline:
3
6
2022
Statut:
epublish
Résumé
The objective of this retrospective study was to explore possible changes in histopathological features and expression of cyclin D1 and MIB-1 in salivary gland pleomorphic adenoma (PA) that recur or undergo malignant transformation. Knowledge of these characteristics might help to guide the management of these rare tumors. The histopathology and immunohistochemical staining characteristics of such tumors were analyzed in a cohort of 65 patients constituting three different groups of tumors: PA, recurrent pleomorphic adenoma (RPA) and carcinoma ex PA (CxPA). The RPAs were divided into two subgroups: primary PA that were known to recur later (PA-prim) and recurrent tumors appearing after a primary tumor (PA-rec). RPAs and CxPAs were compared with PAs without recurrence, which served as a control group. In our study, CxPA and PA-rec, but not PA-prim, showed increased MIB-1 expression compared with the control group. Neither cyclin D1 expression nor any histopathological features showed any association in statistical analyses. CxPA showed increased mitotic activity, squamous metaplasia, and nuclear atypia. Tumor multifocality was more frequent in PA-rec and CxPA. The different MIB-1 expression in CxPA and PA-rec in comparison to PA-prim suggests that the changes in expression could develop after the primary tumor.
Identifiants
pubmed: 35637257
doi: 10.1038/s41598-022-13082-8
pii: 10.1038/s41598-022-13082-8
pmc: PMC9151807
doi:
Substances chimiques
Cyclin D1
136601-57-5
Ubiquitin-Protein Ligases
EC 2.3.2.27
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
9029Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Head Neck Pathol. 2012 Mar;6(1):1-9
pubmed: 21744105
Acta Otorhinolaryngol Ital. 2019 Jun;39(3):156-161
pubmed: 31131834
Head Neck. 2016 Apr;38 Suppl 1:E1364-9
pubmed: 26382619
Diagn Cytopathol. 2017 Jul;45(7):651-654
pubmed: 28261993
Head Neck Pathol. 2013 Sep;7(3):224-31
pubmed: 23315417
Oral Dis. 2018 Mar;24(1-2):98-102
pubmed: 29480608
Gene. 2020 Feb 20;728:144283
pubmed: 31838249
Virchows Arch. 2015 Sep;467(3):295-301
pubmed: 26155914
Head Neck. 2017 Dec;39(12):2416-2424
pubmed: 28945292
Clin Chim Acta. 2019 Apr;491:39-45
pubmed: 30653951
Oral Oncol. 1999 Nov;35(6):583-9
pubmed: 10705094
Acta Oncol. 2006;45(6):669-75
pubmed: 16938809
J Oral Pathol Med. 2012 Sep;41(8):598-602
pubmed: 22530699
Cancer Sci. 2007 May;98(5):629-35
pubmed: 17359287
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503265
Braz J Otorhinolaryngol. 2009 Jul-Aug;75(4):544-9
pubmed: 19784424
Head Neck Pathol. 2013 Jul;7 Suppl 1:S68-76
pubmed: 23821206
Mol Cancer. 2007 Apr 02;6:24
pubmed: 17407548
Histopathology. 2007 Nov;51(5):691-6
pubmed: 17927591
Laryngoscope. 2015 Apr;125(4):888-93
pubmed: 25289881
Endocrinology. 2004 Dec;145(12):5439-47
pubmed: 15331580
Cancer. 2002 Apr 15;94(8):2211-6
pubmed: 12001119
J Mol Med (Berl). 2016 Dec;94(12):1313-1326
pubmed: 27695879
J Cell Physiol. 2000 Mar;182(3):311-22
pubmed: 10653597